Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Minority Interest (2017 - 2025)

Serina Therapeutics (SER) has disclosed Minority Interest for 9 consecutive years, with -$166000.0 as the latest value for Q3 2025.

  • Quarterly Minority Interest fell 207.41% to -$166000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$166000.0 through Sep 2025, down 207.41% year-over-year, with the annual reading at -$133000.0 for FY2024, 100.37% down from the prior year.
  • Minority Interest hit -$166000.0 in Q3 2025 for Serina Therapeutics, down from -$156000.0 in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $36.4 million in Q4 2023 to a low of -$166000.0 in Q3 2025.
  • Historically, Minority Interest has averaged $1.9 million across 5 years, with a median of -$49500.0 in 2022.
  • Biggest five-year swings in Minority Interest: skyrocketed 35443.69% in 2023 and later crashed 420.0% in 2025.
  • Year by year, Minority Interest stood at -$43000.0 in 2021, then plummeted by 139.53% to -$103000.0 in 2022, then surged by 35443.69% to $36.4 million in 2023, then tumbled by 100.37% to -$133000.0 in 2024, then decreased by 24.81% to -$166000.0 in 2025.
  • Business Quant data shows Minority Interest for SER at -$166000.0 in Q3 2025, -$156000.0 in Q2 2025, and -$142000.0 in Q1 2025.